PhaseBio Pharmaceuticals' Series C Round

PhaseBio Pharmaceuticals raised a round of funding on March 12, 2015.

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's …

Articles about PhaseBio Pharmaceuticals' Series C Round: